Coronavirus (COVID-19) Vaccines | CardioSmart – American College of Cardiology
Looking beyond COVID-19 vaccine phase 3 trials | Nature Medicine
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial - eBioMedicine
Adopting a New Agile Approach to CRO Clinical Trial Management - Clinical Trial Services, UK | PHARMExcel
Getting a Flu Vaccine and a COVID-19 Vaccine at the Same Time | CDC
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study | Pediatric Research
UC Davis and Pfizer partner on two new COVID-19 booster vaccine clinical trials
NIH begins clinical trial evaluating second COVID-19 booster shots in adults | National Institutes of Health (NIH)
COVID-19 Boosters: Why You Should Schedule One Now
Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV- BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Coronavirus information
FDA will not require clinical trial data to authorize redesigned COVID boosters -official | Reuters
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Frontiers | Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It
Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial - ScienceDirect
COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG
UK volunteers to receive Moderna Omicron COVID-19 booster vaccine in clinical study | NIHR
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years | NEJM
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial -
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial | Nature Medicine
Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with
Immunobridging trials: Bringing medicines to patients faster
Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel
Homologous and Heterologous Covid-19 Booster Vaccinations | NEJM
